Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells

Molecular and Cellular Endocrinology

Volumn 358, Issue 1, 2012, Pages 104-115

  Nilsson, E M ^a   Brokken, L J S ^a   Narvi, E ^b,c   Kallio, M J ^b,c   Harkonen P L ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Breast tumorigenesis; CDNA microarray; Cyclins; Ingenuity signaling pathway; Mitosis; Nottingham prognostic index

Indexed keywords

AURORA A KINASE; COMPLEMENTARY DNA; CYCLIN B; CYCLIN D1; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 8; POLO LIKE KINASE 1; SURVIVIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; MITOSIS; MOUSE; NONHUMAN; NOTTINGHAM PROGNOSTIC INDEX; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLIN D1; FEMALE; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; INHIBITOR OF APOPTOSIS PROTEINS; MAMMARY NEOPLASMS, ANIMAL; MICE; MITOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84860424403     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.03.009     Document Type: Article

References (55)

1. Balslev I., Axelsson C.K., Zedeler K., Rasmussen B.B., Carstensen B., Mouridsen H.T. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res. Treat. 1994, 32:281-290.
2. Bartkova J., Lukas J., Muller H., Lutzhoft D., Strauss M., Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 1994, 57:353-361.
3. Bleuel K., Popp S., Fusenig N.E., Stanbridge E.J., Boukamp P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl. Acad. Sci. U S A 1999, 96:2065-2070.
4. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 1996, 69:135-174.
5. Castle V.P., Dixit V.M., Polverini P.J. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab. Invest. 1997, 77:51-61.
6. Daphna-Iken D., Shankar D.B., Lawshe A., Ornitz D.M., Shackleford G.M., MacArthur C.A. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene 1998, 17:2711-2717.
7. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A.L., Klijn J.G., Foekens J.A., Cardoso F., Piccart M.J., Buyse M., Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214.
8. Dorkin T.J., Robinson M.C., Marsh C., Bjartell A., Neal D.E., Leung H.Y. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999, 18:2755-2761.
9. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
10. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
11. Galea M.H., Blamey R.W., Elston C.E., Ellis I.O. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res. Treat. 1992, 22:207-219.
12. Gavet O., Pines J. Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. J. Cell Biol. 2010, 189:247-259.
13. Gemel J., Gorry M., Ehrlich G.D., MacArthur C.A. Structure and sequence of human FGF8. Genomics 1996, 35:253-257.
14. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G., Tierney L., Yang J.Y., Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
15. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5:1063-1071.
16. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U S A 1990, 87:6624-6628.
17. Guardavaccaro D., Corrente G., Covone F., Micheli L., D'Agnano I., Starace G., Caruso M., Tirone F. Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol. Cell. Biol. 2000, 20:1797-1815.
18. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
19. Hippo Y., Yashiro M., Ishii M., Taniguchi H., Tsutsumi S., Hirakawa K., Kodama T., Aburatani H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001, 61:889-895.
20. Jeffrey K.L., Camps M., Rommel C., Mackay C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discovery 2007, 6:391-403.
21. Katoh Y., Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int. J. Mol. Med. 2009, 23:307-311.
22. Kawakubo H., Brachtel E., Hayashida T., Yeo G., Kish J., Muzikansky A., Walden P.D., Maheswaran S. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 2006, 66:7075-7082.
23. Kawakubo H., Carey J.L., Brachtel E., Gupta V., Green J.E., Walden P.D., Maheswaran S. Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 2004, 23:8310-8319.
24. Kimura M., Matsuda Y., Eki T., Yoshioka T., Okumura K., Hanaoka F., Okano Y. Assignment of STK6 to human chromosome 20q13.2->q13.3 and a pseudogene STK6P to 1q41->q42. Cytogenet. Cell Genet. 1997, 79:201-203.
25. Lahti J.M., Li H., Kidd V.J. Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1. J. Biol. Chem. 1997, 272:10859-10869.
26. Lens S.M., Voest E.E., Medema R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 2010, 10:825-841.
27. Marsh S.K., Bansal G.S., Zammit C., Barnard R., Coope R., Roberts-Clarke D., Gomm J.J., Coombes R.C., Johnston C.L. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999, 18:1053-1060.
28. Marzioni D., Lorenzi T., Mazzucchelli R., Capparuccia L., Morroni M., Fiorini R., Bracalenti C., Catalano A., David G., Castellucci M., Muzzonigro G., Montironi R. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int. J. Immunopathol. Pharmacol. 2009, 22:627-638.
29. Mattila M.M., Harkonen P.L. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev. 2007, 18:257-266.
30. Mattila M.M., Ruohola J.K., Valve E.M., Tasanen M.J., Seppanen J.A., Harkonen P.L. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001, 20:2791-2804.
31. Mattila M.M., Tarkkonen K.M., Seppanen J.A., Ruohola J.K., Valve E.M., Harkonen P.L. Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells. Mol. Cell. Endocrinol. 2006, 253:36-43.
32. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
33. Nilsson E.M., Brokken L.J., Harkonen P.L. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Exp. Cell Res. 2010, 316:800-812.
34. Olsen S.K., Li J.Y., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 2006, 20:185-198.
35. Otto T., Horn S., Brockmann M., Eilers U., Schuttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., Berwanger B., Eilers M. Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
36. Ruohola J.K., Viitanen T.P., Valve E.M., Seppanen J.A., Loponen N.T., Keskitalo J.J., Lakkakorpi P.T., Harkonen P.L. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001, 61:4229-4237.
37. Saal, L.H., Troein, C., Vallon-Christersson, J., Gruvberger, S., Borg, A., Peterson, C., 2002. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol. 3, SOFTWARE0003.
38. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
39. Sauerbrei W., Hubner K., Schmoor C., Schumacher M. Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res. Treat. 1997, 42:149-163.
40. Schvartzman J.M., Sotillo R., Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer 2010, 10:102-115.
41. Sen S., Zhou H., White R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997, 14:2195-2200.
42. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
43. Team R.D.C. R: a language and environment for statistical computing 2009, R Development Core Team, R Foundation for Statistical Computing.
44. Todd J.H., Dowle C., Williams M.R., Elston C.W., Ellis I.O., Hinton C.P., Blamey R.W., Haybittle J.L. Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer 1987, 56:489-492.
45. Toyoshima-Morimoto F., Taniguchi E., Shinya N., Iwamatsu A., Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001, 410:215-220.
46. Van Horn R.D., Chu S., Fan L., Yin T., Du J., Beckmann R., Mader M., Zhu G., Toth J., Blanchard K., Ye X.S. Cdk1 activity is required for mitotic activation of aurora A during G2/M transition of human cells. J. Biol. Chem. 2010, 285:21849-21857.
47. Wang H.Y., Cheng Z., Malbon C.C. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003, 191:229-237.
48. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., Schmidt E.V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
49. Weaver B.A., Cleveland D.W. The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell 2008, 14:431-433.
50. Weaver B.A., Silk A.D., Montagna C., Verdier-Pinard P., Cleveland D.W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007, 11:25-36.
51. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994, 54:6504-6511.
52. Winkler G.S. The mammalian anti-proliferative BTG/Tob protein family. J. Cell Physiol. 2010, 222:66-72.
53. Volpert O.V., Lawler J., Bouck N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. U S A 1998, 95:6343-6348.
54. Zhang D., Hirota T., Marumoto T., Shimizu M., Kunitoku N., Sasayama T., Arima Y., Feng L., Suzuki M., Takeya M., Saya H. Cre-loxP-controlled periodic aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 2004, 23:8720-8730.
55. Zhang D., Shimizu T., Araki N., Hirota T., Yoshie M., Ogawa K., Nakagata N., Takeya M., Saya H. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene 2008, 27:4305-4314.